ReviewJournal of thoracic disease2025
Allergic bronchopulmonary aspergillosis and
Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BeyondPathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder classically associated with asthma or cystic fibrosis (CF). Recent guidelines have broadened the scope of ABPA to include patients with bronchiectasis, even without underlying asthma or CF. Beyond ABPA, other Methods: We searched PubMed since its inception to June 6, 2025. The keywords included "ABPA" OR "allergic bronchopulmonary aspergillosis" OR "bronchiectasis". Inclusion criteria focused on original studies in English involving bronchiectasis and ABPA, published in peer-reviewed journals. Key Content and Findings: ABPA, AS, and CAI represent a continuum of fungal airway disease shaped by host immune responses. ABPA affects approximately 4% of bronchiectasis patients and may be both a cause and consequence of bronchiectasis. AS and CAI collectively may affect up to 30% of bronchiectasis patients and are independently associated with worse clinical outcomes, including higher bronchiectasis severity scores and increased exacerbation rates. Conclusions: ABPA and related
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.